Driven by US market sales and finished drug exports, Lupin has posted a 46% jump in net profit at Rs 75.6 crore for the quarter ended September 2007 (Q2FY08) when compared with Rs 51.9 crore in Q2FY07.Gross sales for the period grew by 35% to Rs 6,75.6 crore from Rs 4,99.5 crore during Q2FY07.Total export revenues have risen 59% to Rs 329.9 crore. Of these, formulation exports to advanced markets (North America and Europe) constituted 48% at Rs 157 crore. Formulation revenues from domestic market were up 22% Rs 2,60.2 crore.Total formulation revenues from North America and Europe grew 126% to Rs 1,57 crore for the period, said Lupin.
